Wafik S. El-deiry
Department of Hematology/Oncology
Fox Chase Cancer Center
United States of America
Biography
Wafik El-Deiry, MD, PhD, is a Professor of Medicine and Deputy Director of Translational Research at Fox Chase Cancer Center, where he is also Co-Leader of the Molecular Therapeutics Program. He was formerly a Professor of Medicine and Chief of Hematology/Oncology at the Penn State Milton S. Hershey Medical Center. He was also the Associate Director for Translational Research at the Penn State Hershey Cancer Institute. Prior to his tenure at Penn State, he was an assistant investigator in cell biology at the Howard Hughes Medical Institute and an associate professor of medicine at the University of Pennsylvania School of Medicine. Educational Background :Fellow, Medical Oncology, Johns Hopkins Oncology Center, Baltimore, MD, 1994 Resident, Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, 1990 MD/PhD, Biochemistry, University of Miami School of Medicine, Miami, FL, 1987 BS, Chemistry, University of Miami, Coral Gables, FL, 1981
Research Interest
Gastrointestinal cancers, Drug Development, Precision Medicine . Drug Development Targeting Cell Death in Colorectal & Other Cancers . Cell death signaling involving TRAIL death receptors and the p53 tumor suppressor gene/drug resistance mechanisms. Novel therapeutics targeting mutant p53 in human cancer. Combinatorial therapeutics and resistance mechanisms to ONC201/TIC10. Liquid biopsy applications in cancer management. Immunophenotyping Circulating tumor cells. Precision Medicine; impact on genomics on cancer therapy. Targeting the hypoxic tumor microenvironment. Targeting cancer stem cells.
Publications
-
Wagner, J., Kline, C. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Dicker, D. T., ... & El-Deiry, W. S. (2014). The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget, 5(24), 12728.
-
Allen, J. E., Prabhu, V. V., Talekar, M., van den Heuvel, A. P. J., Lim, B., Dicker, D. T., ... & El-Deiry, W. S. (2015). Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10. Cancer research, 75(8), 1668-1674.
-
Prabhu, V. V., Allen, J. E., Dicker, D. T., & El-Deiry, W. S. (2015). Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem–like cells in an Akt/Foxo3a/TRAIL–dependent manner. Cancer research, 75(7), 1423-1432.
-
Prabhu, V. V., Allen, J. E., Dicker, D. T., & El-Deiry, W. S. (2015). Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem–like cells in an Akt/Foxo3a/TRAIL–dependent manner. Cancer research, 75(7), 1423-1432.
-
Li, P., Mao, Z., Peng, Z., Zhou, L., Chen, Y., Huang, P. H., ... & Suresh, S. (2015). Acoustic separation of circulating tumor cells. Proceedings of the National Academy of Sciences, 112(16), 4970-4975.
-
Zhang, S., Zhou, L., Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Warfel, N. A., ... & El-Deiry, W. S. (2015). Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer research, 75(18), 3842-3852.
